Escolar Documentos
Profissional Documentos
Cultura Documentos
© Opel
© Opel
Key Discussion Points
• PACV Research
• Development and Initial Validation
• Ongoing Evaluations of PACV
• PACV Applications
• Descriptive measure
• Surveillance tool
• Outcome measure
• Clinical screening tool
© Opel
Key Discussion Points
• PACV Research
• Development and Initial Validation
• Ongoing Evaluations of PACV
• PACV Applications
• Descriptive measure
• Surveillance tool
• Outcome measure
• Clinical screening tool
© Opel
Development and Validation of the PACV
Test of Test of
Survey
Construct Predictive
development
Validity Validity
© Opel
Health Belief Model
Concept Definition
Perceived susceptibility Beliefs about the chances of getting a
condition
Perceived severity Beliefs about the seriousness of a condition
and its consequences
Perceived benefits Beliefs about the effectiveness of taking
action to reduce risk or seriousness
Perceived barriers Beliefs about the material and psychological
costs of taking action
Cues to action Factors that activate ”readiness to change”
© Opel
4 Step Process for PACV Development
ITEM SELECTION
12 items modified from existing relevant survey instruments, 5 items constructed de novo
[17 total survey items]
ITEM REDUCTION
9 items deleted based on the review of a panel of experts (N=6) who rated each item’s
significance in being able to identify vaccine hesitant parents
[18 total survey items]
PRETESTING
1 item added, 1 item deleted, and format changes made based upon cognitive interviews and
feedback from parents (N=25)
[18 total survey items in preliminary survey]
15 All things considered, how much do you trust your child’s doctor? © Opel 0-10 scale
Test of the PACV’s Construct Validity
70
Percent days under-
60
immunized
50
40
30
20
10
0
0-49 (ref) 50-79 80-100
Overall PACV Score
Opel et al. Vaccine 2011
© Opel
Test of the PACV’s Predictive Validity
90
Percent Days Under-
80
70
PACV Score ≥50
Immunized
60
50
40
30
20
10
0
0-9 (ref) 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-100
-10
© Opel
Ongoing evaluations of the PACV
© Opel
Performance of PACV in parent population
in Nashville, TN, USA
© Opel
© Opel
Key Discussion Points
• PACV Research
• Development and Initial Validation
• Ongoing Evaluations of PACV
• PACV Applications
• Descriptive measure
• Surveillance tool
• Outcome measure
• Clinical screening tool
© Opel
PACV as surveillance tool
© Opel
PACV as an outcome measure
100%
98%
96%
94% 12.6% 8.0% 9.8% 7.5%
92%
90% PACV ≥50
88% PACV <50
86%
84% Adjusted
82% OR: 1.22
(0.47, 2.68)
80%
Control Control Intervention Intervention
(Baseline) (6 months) (Baseline) (6 months)
© Opel
Validation of the PACV short scale
© Opel
Conclusion
• PACV is one of several tools to measure vaccine hesitancy
• Integration into clinical setting and as public health
surveillance tool are newest applications
• Adaptation to and evaluation in your own setting is
encouraged
© Opel
Acknowledgements
Thank you!
• Seattle Children’s • Other
• Rita Mangione-Smith MD, MPH • Jeff Robinson PhD (Portland State)
• Jan Englund MD • John Heritage PhD (UCLA)
• Chuan Zhou PhD • Rachel Cunningham MPH (TCH)
• Ed Marcuse MD, MPH • Julie Boom MD (TCH)
• Annika Hofstetter MD, PhD, MPH • S. Elizabeth Williams MD
(Vanderbilt)
• University of Washington • Jimmy Roberts MD (MUSC)
• Jim Taylor MD
• Paul Darden MD (Oklahoma)
• Ali Rowhani-Rahbar MD, MPH, PhD
• Dan Kahan JD (Yale)
• Group Health Research Institute • WA Dept of Health
• Nora Henrikson PhD • Michele Roberts
• John Dunn MD, MPH • Paul Throne
• David Grossman MD, MPH
• Melissa Anderson MS • Funding: K23HD069467 (NIH),
1R21HD083770-01A1 (NIH), Seattle
Children’s Research Institute
© Opel